ClinicalTrials.gg
RecruitingNCT06735248Updated Jun 15, 2026

A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years

A Phase 2 interventional study of mRNA-1195 and Placebo in Multiple Sclerosis, sponsored by ModernaTX, Inc.. Recruiting at 17 sites in 3 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-06-15.

Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,192 studies in Multiple Sclerosis with a site in United States — 184 open to participants now, 259 under way, 23 of them phase 3. Multiple Sclerosis · United States.

Planned enrollment
172nd of 879
180 · median 50
Started
2025
with 56 others
Phase 2
139 of 1,192
20 open now
Primary completion
2029-01
later than 199 of 256 live
Registered
1,090th of 1,192
by date

Among the 1,192 studies in Multiple Sclerosis with a site in United States, this one is the 172nd largest by planned enrollment of the 879 interventional ones that give a count, is one of 57 that started in 2025, is one of 139 in phase 2, reaches primary completion later than 199 of the 256 other live ones, and was the 1,090th registered.

Multiple Sclerosis

3,272 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

184 of the 1,192 studies in Multiple Sclerosis with a site in United States are open now. Recruiting first, the newest first:

179 more — sign in →

All 184 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 432 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 213 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,192 studies in Multiple Sclerosis with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this trial is to evaluate the safety and reactogenicity of mRNA-1195 in participants with multiple sclerosis.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

Keywords

  • Multiple Sclerosis
  • mRNA-1195
  • MS
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Medically stable as determined by Investigator's medical evaluation, which will include assessment of medical history, physical examination, laboratory testing, and review of any previously conducted cardiac monitoring.
  • Participants who are Epstein-Barr virus (EBV)-seropositive at screening.
  • Participants diagnosed with relapsing multiple sclerosis, including those with a single clinical attack (that is, clinically isolated syndrome [CIS]), as well as participants diagnosed with radiologically isolated syndrome, within 24 months of Screening Visit (that is, early in their multiple sclerosis course) and in the opinion of the Investigator have been neurologically stable for at least 30 days prior to Visit 1/Day 1.
  • A participant who could become pregnant is eligible to participate if they are not pregnant or breast/chest feeding and using a highly effective method.

Exclusion criteria

Exclusion Criteria:

  • Acutely ill or febrile (temperature ≥38.0 degrees Celsius (℃) [100.4 Fahrenheit °F]) within 72 hours prior to or at screening or Day 1.
  • History of a diagnosis or condition that, in the judgment of the Investigator, is clinically unstable or may affect participant safety, assessment of study endpoints, assessment of immune response, or adherence to study procedures.
  • Received or plans to receive any non-study vaccine (including authorized or approved vaccines for the prevention of coronavirus disease 2019 [COVID-19] regardless of vaccine type) within 28 days before or after any study injection, or within 14 days before or after any study injection for the influenza vaccine.
  • Any medical, psychiatric, or occupational condition, including reported history of drug or alcohol abuse, that, in the opinion of the Investigator, might pose additional risk due to participation in the study or could interfere with the interpretation of study results.
  • Received systemic within the 30 day period prior to screening (for , ≥10 milligrams (mg)/day of prednisone or equivalent)
  • Participants with any documented history of myocarditis, pericarditis, or myopericarditis.
  • Has donated ≥450 milliliter (mL) of blood products within 28 days prior to screening or plans to donate blood products within 28 days post-study injection.

Note: Other inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    mRNA-1195 Dose Level 1 (Low Dose)

    Participants will receive 3 intramuscular (IM) injections at dose level 1 (low dose) on a 0-, 2-, and 6-month schedule.

    Biological: mRNA-1195

  • Experimental
    mRNA-1195 Dose Level 2 (High Dose)

    Participants will receive 3 IM injections at dose level 2 (high dose) on a 0-, 2-, and 6-month schedule.

    Biological: mRNA-1195

  • Placebo comparator
    Placebo

    Participants will receive 3 placebo IM injections on a 0-, 2-, and 6-month schedule.

    Biological: Placebo

Interventions

  • BiologicalmRNA-1195

    IM injection

  • BiologicalPlacebo

    IM injection

06

What researchers measure

Primary outcomes

  1. Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)

    Time frame: Up to Day 176 (7 days after each study injection)

  2. Number of Participants with Unsolicited Adverse Events (AEs)

    Time frame: Up to Day 197 (28 days after each study injection)

  3. Number of Participants with Medically Attended Adverse Events (MAAEs)

    Time frame: Up to Day 347 (up to 6 months after last study injection)

  4. Number of Participants with Adverse Events of Special Interest (AESI), Serious Adverse Events (SAEs) and AEs Leading to Discontinuation of Study Intervention and/or Study Participation

    Time frame: Up to Day 887 (end of study)

Secondary outcomes

  1. Cumulative Number of New Gadolinium (Gd)-enhancing Longitudinal Relaxation Time (T1) Hyperintense Lesions, as Measured by Magnetic Resonance Imaging (MRI) from Baseline to Month 12 and End of Study (Day 887)

    Time frame: Baseline to Month 12 and Day 887 (end of study)

  2. Mean Number of Gd-enhancing T1 Hyperintense Lesions Per Scan, as Measured by MRI from Baseline to Month 12 and End of Study (Day 887)

    Time frame: Baseline to Month 12 and Day 887 (end of study)

  3. Cumulative Number of New and/or Newly Enlarging Transverse Relaxation Time (T2)-weighted Hyperintense Lesions as Measured by MRI from Baseline to Month 12 and End of Study (Day 887)

    Time frame: Baseline to Month 12 and Day 887 (end of study)

  4. Time to First New Disease Activity on Study as Defined by a Clinical Attack Indicative of Central Nervous System (CNS) Involvement at a Site Remote to the First Attack or a New and/or Newly Enlarging T2 or Gd-enhancing Lesion on MRI

    Time frame: Up to Day 887 (end of study)

  5. Geometric Mean Titer (GMT) of B-cell Neutralizing Antibodies (nAbs) and/or Vaccine Antigen-specific Binding Antibodies (bAbs) at Days 1, 85, and 197

    Time frame: Days 1, 85, and 197

  6. Geometric Mean Fold Rise (GMFR) of B-cell nAbs and/or Vaccine Antigen-specific bAbs at Days 1, 85, and 197

    Time frame: Days 1, 85, and 197

  7. Change in Expanded Disability Status Scale (EDSS) Score at 3- and 6-month Intervals from Baseline to End of Study (Day 887)

    Time frame: Baseline, Day 887 (end of study)

  8. Time to 6-month Confirmed Disability Progression

    Time frame: Up to Day 887 (end of study)

07

Study locations

15 of 17 sites recruiting
  • Boston Clinical Trials Inc - Internal Medicine
    Boston, Massachusetts 02131, United States
    Terminated

    Not enrolling at this site.

  • Quest Research Institute
    Farmington Hills, Michigan 48334, United States
    Recruiting
  • Sharlin Health & Neurology
    Ozark, Missouri 65721, United States
    Terminated

    Not enrolling at this site.

  • Washington University School of Medicine Neurology Clinical Unit
    St Louis, Missouri 63110, United States
    Recruiting
  • Oklahoma Medical Research Foundation (OMRF) MS Center of Excellence
    Oklahoma City, Oklahoma 73104, United States
    Recruiting
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390-8806, United States
    Recruiting
  • ANESC Research
    El Paso, Texas 79912, United States
    Recruiting
    • Frank Chairz · Contactfchairez@anesc.net · 915-974-2200
    • Aamr Herekar, MD · Principal investigator
  • Saturn Research Solutions
    Plano, Texas 75024, United States
    Recruiting
  • University of the Sunshine Coast Clinical Trials
    Birtinya, Queensland 04575, Australia
    Recruiting
  • North Bristol NHS Trust - Southmead Hospital
    Bristol, BS10 5NB, United Kingdom
    Recruiting
  • Cardiff and Vale University Health Board - University Hospital Wales
    Cardiff, CF14 4XW, United Kingdom
    Recruiting
  • Anne Rowling Regenerative Neurology Clinic, University of Edinburgh
    Edinburgh, EH16 4SB, United Kingdom
    Recruiting
  • NHS Greater Glasgow & Clyde - Institute of Neurological Sciences
    Glasgow, G51 4TF, United Kingdom
    Recruiting
  • Cambridge Clinical Research Centre
    London, CB2 0SL, United Kingdom
    Recruiting
  • East Kent Hospitals University NHS Foundation Trust
    London, CT1 3NG, United Kingdom
    Recruiting
  • The Newcastle Upon Tyne Hospitals NHS Foundation Trust
    Newcastle upon Tyne, NE14LP, United Kingdom
    Recruiting
  • Sheffield Teaching Hospital NHS foundation Trust, Herries Road
    Sheffield, S10 2JF, United Kingdom
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Jan 2029, 44 months after the start.

Of 43 industry-sponsored phase 2 interventional studies under Multiple Sclerosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 47. This study's planned 44 months is above that.

Counting every sponsor, half of 92 studies reached it within 36 months; a quarter within 19 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2024
First posted
Dec 16, 2024
StartActual
Apr 16, 2025
Primary completionEst.
Jan 8, 2029
CompletionEst.
Jan 8, 2029
Last update
Jun 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06735248
Lead sponsor
ModernaTX, Inc.
Responsible party
Sponsor
First posted
Dec 16, 2024
Start date
Apr 16, 2025
Primary completion
Jan 8, 2029 (estimated)
Completion
Jan 8, 2029 (estimated)
Last update
Jun 15, 2026

Study contacts

Moderna WeCare Team
Contact
WeCareClinicalTrials@modernatx.com
1-866-663-3762

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion